Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines.
authentication
cancer
cell line
isogenic
mass spectrometry
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
02 10 2019
02 10 2019
Historique:
received:
06
08
2019
revised:
22
09
2019
accepted:
27
09
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
14
8
2020
Statut:
epublish
Résumé
The use of cell lines in research can be affected by cell line misidentification. Short tandem repeat (STR) analysis is an effective method, and the gold standard, for the identification of the genetic origin of a cell line, but methods that allow the discrimination between cell lines of the same genetic origin are lacking. Here, we use intact cell MALDI-ToF mass spectrometry analysis, routinely used for the identification of bacteria in clinical diagnostic procedures, for the authentication of a set of cell lines consisting of three parental neuroblastoma cell lines (IMR-5, IMR-32 and UKF-NB-3) and eleven drug-adapted sublines. Principal component analysis (PCA) of intact-cell MALDI-ToF mass spectrometry data revealed clear differences between most, but not all, of the investigated cell lines. Mass spectrometry whole-cell fingerprints enabled the separation of IMR-32 and its clonal subline IMR-5. Sublines that had been adapted to closely related drugs, for example, the cisplatin- and oxaliplatin-resistant UKF-NB-3 sublines and the vincristine- and vinblastine-adapted IMR-5 sublines, also displayed clearly distinctive patterns. In conclusion, intact whole-cell MALDI-ToF mass spectrometry has the potential to be further developed into an authentication method for mammalian cells of a common genetic origin.
Identifiants
pubmed: 31581737
pii: cells8101194
doi: 10.3390/cells8101194
pmc: PMC6830094
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Vincristine
5J49Q6B70F
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/K017640/1
Pays : United Kingdom
Références
BMC Genomics. 2014 Oct 03;15:847
pubmed: 25277546
Mol Cancer Ther. 2009 Apr;8(4):713-24
pubmed: 19372543
Bioanalysis. 2013 Apr;5(8):885-93
pubmed: 23590472
Sci Rep. 2015 Feb 03;5:8202
pubmed: 25644037
Science. 1992 Dec 4;258(5088):1650-4
pubmed: 1360704
Nature. 2015 Apr 16;520(7547):307-11
pubmed: 25877200
J Exp Med. 1953 May;97(5):695-710
pubmed: 13052828
Invest Ophthalmol Vis Sci. 2013 Aug 23;54(8):5712-9
pubmed: 23975727
Methods Mol Biol. 2013;1061:197-209
pubmed: 23963939
Cancer Cell. 2012 Sep 11;22(3):373-88
pubmed: 22975379
Anal Bioanal Chem. 2012 Nov;404(8):2277-86
pubmed: 22955673
Natl Cancer Inst Monogr. 1967 Sep;26:167-95
pubmed: 4864103
Nature. 2010 Dec 16;468(7326):973-7
pubmed: 21107323
Int J Cancer. 2010 Jan 1;126(1):303-4
pubmed: 19859913
Int J Cancer. 2018 Feb 1;142(3):561-572
pubmed: 28940260
Int J Oncol. 2005 Oct;27(4):1029-37
pubmed: 16142320
Nature. 2011 Nov 23;480(7377):387-90
pubmed: 22113612
Nature. 2014 Jul 3;511(7507):90-3
pubmed: 24870236
Nat Med. 2017 Feb;23(2):250-255
pubmed: 27991919
Rapid Commun Mass Spectrom. 2011 May 30;25(10):1407-12
pubmed: 21504006
Int J Cancer. 2013 Jun 1;132(11):2510-9
pubmed: 23136038
Rapid Commun Mass Spectrom. 2010 May 15;24(9):1226-30
pubmed: 20391592
FASEB J. 2015 Oct;29(10):4268-72
pubmed: 26116706
Int J Cancer. 1999 Nov 12;83(4):555-63
pubmed: 10508494
Cancer Genet Cytogenet. 2006 Apr 1;166(1):56-64
pubmed: 16616112
Science. 1977 Mar 25;195(4284):1343-4
pubmed: 557237
J Biotechnol. 2014 Aug 20;184:84-93
pubmed: 24858576
J Virol Methods. 2010 Mar;164(1-2):116-21
pubmed: 19941903
Nat Rev Cancer. 2010 Jun;10(6):441-8
pubmed: 20448633
Anal Bioanal Chem. 2011 Jul;401(1):135-47
pubmed: 21553124
J Natl Cancer Inst. 1960 Aug;25:359-85
pubmed: 13815376
Nucleic Acids Res. 2009 Jan;37(Database issue):D925-32
pubmed: 18927105
Cell Death Dis. 2011 Dec 15;2:e243
pubmed: 22170099
Cancer Discov. 2013 Sep;3(9):1020-9
pubmed: 23779130
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Nature. 2011 Mar 24;471(7339):523-6
pubmed: 21430781
Science. 2014 Dec 19;346(6216):1480-6
pubmed: 25394791
PLoS One. 2017 Jan 20;12(1):e0170384
pubmed: 28107433
Cancer Res. 1996 Jul 1;56(13):2992-7
pubmed: 8674053
Cancer Genet Cytogenet. 1996 Mar;87(1):14-23
pubmed: 8646734
Arch Pathol Lab Med. 2009 Sep;133(9):1463-7
pubmed: 19722756
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7
pubmed: 11416159
BMC Biotechnol. 2015 Apr 11;15:24
pubmed: 25887592
Gene. 2005 Dec 19;363:41-50
pubmed: 16216448
Nat Med. 2016 Mar;22(3):262-9
pubmed: 26828195
In Vitro Cell Dev Biol Anim. 1996 May;32(5):262-4
pubmed: 8792154
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
pubmed: 990323
Cancer Discov. 2013 Sep;3(9):1030-43
pubmed: 23842682
J Am Soc Mass Spectrom. 2006 Apr;17(4):490-499
pubmed: 16488154
Cell Death Dis. 2012 Apr 05;3:e294
pubmed: 22476102
Methods Mol Biol. 2013;946:27-38
pubmed: 23179824
Cancer Res. 1981 Apr;41(4):1508-17
pubmed: 6260341
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Oncogene. 2011 Nov 17;30(46):4678-86
pubmed: 21643018
Cancer Genet Cytogenet. 1997 Dec;99(2):108-15
pubmed: 9398864
Nat Med. 2017 Jan;23(1):69-78
pubmed: 27941792
Cancer Res. 2017 Jun 1;77(11):2784-2788
pubmed: 28455420
Rapid Commun Mass Spectrom. 2008 Apr;22(8):1099-108
pubmed: 18335464
Nat Commun. 2016 Aug 31;7:12609
pubmed: 27576846
J Microbiol Methods. 2017 Jul;138:20-29
pubmed: 27613479
J Natl Cancer Inst. 1962 Jan;28:147-57
pubmed: 13872458